^
Association details:
| Biomarker: | ALK wild-type |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
Published date:
03/09/2022
Excerpt:
Human lung cell line BEAS-2B and malignant A549 lung cancer cells (ALK/ROS1 wt) were treated with alectinib or crizotinib….Crizotinib led to higher cell death rates than alectinib, when cells were treated with 10 µM KI. Alectinib induced a more intense growth inhibition of colonies....Crizotinib resulted in a stronger response at highest concentration of 10 µM in BEAS-2B (10 µM + 2 Gy: 76.4 %) and A549 (10 µM + 2 Gy: 65.2 %) compared to alectinib (BEAS-2B, 10 µM + 2 Gy: 35.3 %; A549, 10 µM + 2 Gy: 44.5 %).
DOI:
10.1016/j.neo.2022.100780
